natgillin/translations-raw huggingface dataset:
A compound according to any one of claims 1-11 for use in the treatment of one or more of compromised lactation conditions, labour induction impairment, uterine atony conditions, excessive bleeding, inflammation, pain, abdominal pain, back pain, male and female sexual dysfunction, irritable bowel syndrome (IBS), constipation, gastrointestinal obstruction, autism, stress, anxiety, depression, anxiety disorder, surgical blood loss, post-partum haemorrhage, wound healing, infection, mastitis, placenta delivery impairment, osteoporosis, and/or for the diagnosis of cancer and placental insufficiency. 
Spoj prema bilo kojem od zahtjeva 1-3, naznačen time da se upotrebljava u liječenju jednog ili više narušenih uvjeta dojenja, oštećenja nakon induciranog poroda, uvjeta atonije maternice, pretjeranog krvarenja, upale, boli, abdominalne boli, boli leđa, muške 1 ženske seksualne disfunkcije, sindroma iritabilnog crijeva (1B5), zatvora, gastrointenstinalnog začepljenja, autizma, stresa, anksioznosti, depresije, poremećaja anksioznosti, gubitka krvi uslijed kirurških zahvata, postporođajnog krvarenja, zacjeljivanja rana, infekcije, mastitisa, oštećenja porođajne posteljice i osteoporoze.
As SDS removal proceeds, a concentration is reached below which the size of the aggregates starts to increase exponentially (see Figure 1). 
Kako se odstranjivanje SDS nastavlja, kocentracija se dostiže ispod koje veličina agregata počinje da raste eksponencijalno (vidi Sliku 1).
The method according to claim 11, further comprising the procedure of determining characteristics (288) of said threat source based on said pulse mappings, said characteristics selected from the list consisting of: 
Metoda u skladu sa zahtjevom 7, naznačena time što su navedene karakteristike navedenog izvora prijetnje odabrane s popisa koji sadrži:
Specifically, the layer C presents particles P of crosslinked PMMA, finely dispersed in a matrix M of extruded PMMA, such particles presenting a diameter less than 200 micron. 
Konkretno, sloj C ima čestice P od umreženog PMMA, koje su raspršene u matrici M od ekstrudiranog PMMA, pri čemu takve čestice imaju promjer koji je manji od 200 mikrona.
A compound of formula (I) according to claim 1 selected from the group and their pharmaceutically acceptable salts. 
Spoj formule (I), kladu s patentnim zahtjevom 1, kojeg se bira iz skupine
The protective wrapping according to any one of the preceding claims, wherein all components of the protective wrapping are selected to be suitable for recycling together. 
Zaštitni omotač u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se sve komponente zaštitnog omotača bira da budu pogodne za zajedničko Tecikliranje.
A method of making a genetically modified non-human animal, comprising modifying a non-human animal genome to comprise at an endogenous Major Histocompatibility Complex II (MHC II) a gene locus a first nucleotide sequence encoding a chimeric human/non-human MHC II a polypeptide and/or at an endogenous Major Histocompatibility Complex II (MHC II) B gene locus a second nucleotide sequence encoding a chimeric human/non-human MHC II B polypeptide, wherein a human portion of the chimeric human/non-human MHC II a polypeptide comprises human MHC II a1 and a2 extracellular domains and/or a human portion of the chimeric human/non-human MHC II B polypeptide comprises human MHC II B1 and B2 extracellular domains, and wherein the chimeric human/non-human MHC II a and/or MHC II B polypeptides form a functional MHC II complex on a surface of a cell of the non-human animal. 
Postupak proizvodnje genetski modificiranog glodavca, naznačen time, da obuhvaća modificiranje genoma glodavca u svrhu obuhvaćanja, na endogenom a-gen-lokusu glavnog histokompatibilnog kompleksa II (MHC II), prve nukleotidne sekvence koja kodira kimerni ljudski/glodarski MHC II-a-polipeptid, i/ili na endogenom B-gen-lokusu glavnog histokompatibilnog kompleksa II (MHC II), druge nukleotidne sekvence koja kodira kimerni ljudski/glodarski MHC II-B-polipeptid, pri čemu ljudski dio kimernog ljudskog/glodarskog MHC II-a-polipeptida, sadrži ljudske izvanstanične MHC II-a1 i -a2 domene i/ili ljudski dio kimernog ljudskog/glodarskog MHC II-B-polipeptida, sadrži ljudske izvanstanične MHC II-B1 i -B2 domene, i pritom kimerni ljudski/glodarski MHC II-a- i/ili MHC II-B-polipeptidi, tvore funkcionalni MHC II-kompleks na površini stanice glodavca.
At 10 mg/kg, the waking effect occurred as early as the first hour after treatment, animals being almost permanently wakeful for 6-12 h. 
Pri 10 mg/kg, učinak buđenja dogodio se rano u prvom satu nakon tretmana, životinje su bile budne tijekom 6-12 sati.
The apparatus of claim 1, wherein the entropy coder scans the non-zero coefficients of each subset in a reverse direction using one of a plurality of scan patterns. 
Uređaj prema zahtjevu 1, naznačen time da entropijski koder (130) kodira položaje ne-nultih koeficijenata i informacije za identifikaciju ne-nultih koeficijenata svakog pod-bloka.
to make available a determinate quantity of basic compound, able to achieve a buffer effect of said trichloracetic acid comprised in said first mixture; 
osiguravanje određene količine bazičnog spoja, kako bi postiglo pufersko djelovanje navedene trikloroctene kiseline sadržane u navedenoj prvoj smjesi;
This application is intended to cover any variations, uses or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth as follows in the scope of the appended claims. 
Ova predstavka pokriva sve varijacije, primjene ili prilagodbe izuma slijedeći, u principu, načela izuma i uključujući sve odmake od opisanog priopćenja znane i uobičajene u praksi struke na koju se izum odnosi i koji se mogu primijeniti na osnovne značajke ovdje predstavljene kako slijedi u opsegu pridodanih patentnih zahtijeva. HR P20070474 T3
modulating (S1705) the signal frame by an OFDM method; and 
Dodlaljivanje simbola PLP-a okviru signala i
Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; or 
Prsten A je opcionalno supstituirani nezasićeni monociklički heterociklički prsten, i Prsten B je opcionalno supstituirani nezasićeni monociklički heterociklički prsten, opcionalno supstituirani nezasićeni srašteni heterobiciklički prsten, ili opcionalno supstituirani benzenov prsten; ili
A pharmaceutical composition comprising a compound having the structure shown in claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, for use in the treatment of a disease or disorder which is selected from breast cancer, multiple myeloma, glioblastoma, and lymphoma. Use of a compound having the structure shown in claim 1 or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating a disease or disorder selected from breast cancer, multiple myeloma, glioblastoma, and lymphoma. 
Spoj ili sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je rak gušterače. Spoj ili sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je rak kože. Uporaba spoja prema zahtjevu 1, ili njegove farmaceutski prihvatljive soli, naznačena time, da je za proizvodnju lijeka za liječenje bolesti ili poremećaja povezanih sa nekontroliranim, nenormalnim i/ili neželjenim staničnim djelovanjima.
inserting the partly AX-REED treated liquid into the chamber for the staring liquid 
VI. ubacivanje djelomično obrađene tekućine s AX-REED u komoru za početnu tekućinu;
a conversion tank adapted for holding the pressurized and heated feed mixture for a predetermined process time; 
– konverzijski spremnik, prilagođen za držanje stlačene i zagrijane dovodne smjese kroz zadano vrijeme obrade;
wherein said HDAC inhibitor is a compound of the following formula or a pharmaceutically acceptable salt thereof: 
HDAC inhibitor, pri čemu je HDAC inhibitor spoj sa sljedećom formulom: [image] i arginin.
The compound according to embodiment 1 selected from the group consisting of: 
Spoj prema patentnom zahtjevu 1, naznačen time, da se odabire iz skupine koja sadrži:
The engine of 1 comprising the ratio of cylinder volumes from BDC to TDC for either one of the expansion cylinder and compression cylinder being substantially 40 to 1 or greater. 
Motor (100) iz bilo kojeg prethodnog patentnog zahtjeva, naznačen time što je omjer volumena cilindra od DMT do GMT za ekspanzijski (104) cilindar ili za kompresijski (106) cilindar približno 40 prema 1 ili veći.
Aqueous dispersion of claim 1) in which the anionic polyurethane is prepared by reacting an anionic prepolymer A) containing from 10 to 25 meq/100 g dry matter of carboxylic groups. 
Vodena disperzija u skladu s patentnim zahtjevom 1), naznačena time što se anionski poliuretan pripravlja reakcijom anionskog prepolimera A) koji sadrži od 10 do 25 meq/100 g suhe tvari karboksilnih skupina.
An N -oxide derivative of a compound of formula (I) as defined in claim 1, or a pharmaceutically acceptable salt or solvate thereof. 
N-oksid derivat spoja formule (I) kako je definirano u patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol ili solvat.
the amino acid sequences of SEQ ID NOs: 34, 39, and 75, respectively; 
(viii) glicin na položaju 8 u petlji BC (SEQ ID NO: 34) je zamijenjen aminokiselinom S;
As a further object, the present invention concerns also methods for preparing the dihydrospiro-[cycloalkylamine]-pyrimidone compounds represented by the aforementioned formula (I). 
Daljnji cilj ovog izuma su postupci dobivanja dihidrospiro[cikloalkilamin]pirimidonskih spojeva, prikazanih gore navedenom formulom (1).
detecting the amplicons so produced, wherein detection of presence of both amplicons indicates that said sample is heterozygous for corn event MON89034 DNA, wherein detection of only the first amplicon indicates that said sample is homozygous for corn event MON89034 DNA. 
(c) detekciju amplikona dobivenih na ovaj način, pri čemu otkrivanje prisutnosti oba amplikona ukazuje da je navedeni uzorak heterozigotan za DNA kukuruza oznake MON89034, pri čemu otkrivanje samo prvog amplikona upućuje da je navedeni uzorak homozigotan za DNA kukuruza oznake MON89034.
means (17) for covering at least two flexible tubes (18, 19), which are already covered with said insulating tape and are arranged mutually side-by-side and parallel, with a protection and containment sheath (20), 
- > sredstvo (17) za prekrivanje najmanje dvije savitljive cijevi (18, 19), a koje su već prekrivene navedenom izolacijskom trakom te su postavljene međusobno jedna uz drugu i paralelno, oblogom namijenjenom zaštiti 1 sapinjanju (20);
Figure 1 is a perspective view of an exemplary embodiment of the blender system; 
Slika 1 prikaz je primjera ostvarenja sustava mješalice;
A packaging according to any of claims 1-5, wherein the first and second outer part has a U-shaped cross-section, the legs of the U-shape comprising protrusions for retaining the inner part. 
Pakiranje u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačeno time, što prvi i drugi vanjski dio ima Uoblikovan poprečni presjek, pri čemu krakovi U-oblikovanog presjeka sadržavaju izbočenja za držanje unutarnjeg dijela.
a dose of 1 to 1014 particles per kilogram of patient weight; or a dose of 106 to 1012 particles per kilogram of patient weight. 
Polipeptid za uporabu, sukladno zahtjevima 1-2, naznačen time, da tretman započinje oralnim putem, parenteralnim putem, rektalnim putem, inhalacijom ili upuhivanjem.
Solutions for injections may be prepared by dissolving the active ingredient and possible additives in a part of the solvent for injection, preferably sterile water, adjusting the solution to the desired volume, sterilising the solution and filling it in suitable ampoules or vials. 
Otopine za injekcije mogu se pripraviti rastapanjem aktivne tvari I mogućih aditiva u jednom dijelu otapala za injekcije, preferira se sterilna voda, prilagođavajući otopinu željenoj količini, uz sterilizaciju otopine T punjenja u odgovarajuće ampule ili epruvete.
A method of administering a compound to a mammal comprising the steps of: combining the compound selected from the group consisting of: 
(a) kombiniranje spoja u skladu s patentnim zahtjevom 1, koji se odabire iz skupine koju čine: po
The use of claim 5, wherein the angiogenesis-related disorder is cancer or age-related macular degeneration. 
Uporaba prema patentnom zahtjevu 5, naznačena time da je poremećaj povezan sa angiogenezom rak ili makularna degeneracija povezana sa dobi.
2.5 liters) contains the pre-mix of inoculant and water. 
od 2,5 1) sadrži prethodno pomiješan inokulant i vodu.
6% by weight levodopa, 1.5% by weight carbidopa, 1% by weight Na-ascorbate, and 13.5%, 14.2%, 14.8% or 16.0%, by weight arginine; 
6% masenog udjela levodopa, 1,5% masenog udjela karbidopa, 1% masenog udjela natrijevog askorbata, i 13,5%, 14,2%, 14,8% ili 16,0% masenog udjela arginina;
3% (1 grade improvement) 3% (2 grade improvement) 
3% (poboljšanje 1. stupnja) 3% (poboljšanje 2. stupnja)
Suitable antagonists for preventing abuse of the active ingredients are known per se to the person skilled in the art and may be present in the dosage form according to the invention as such or in the form of corresponding derivatives, in particular esters or ethers, or in each case in the form of corresponding physiologically acceptable compounds, in particular in the form of the salts or solvates thereof. 
Prikladni antagonisti za sprečavanje zlouporabe djelatnih tvari su poznati stručnjaku i kao takvi mogu u obliku davanja prema izumu biti prisutni u obliku odgovarajućih derivata, osobito estera ili etera, ili u obliku odgovarajućih fiziološki podnošljivih spojeva, osobito u obliku njihovih soli ili solvata.
The systems comprised 40 liters or 350 liters bioreactors connected to external columns as described in Example 1.1. 
Sustavi su obuhvaćali bioreaktore od 40 litara pa do 350 litara koji su bili povezani na vanjske kolone kako je opisano u Primjeru 1.1.
to 30 wt.%, particularly 1 to 10 wt.% and preferably 2 to 8 wt.% of said bioadhesive material; and 
0,5 do 30 masenih %, posebno 1 do 10 masenih % i poželjno 2 do 8 masenih % navedenog bioljepljivog materijala; i
The method of claim 17, wherein the Compound I hydrogen malonate is prepared in a alcohol solvent. 
Postupak prema zahtjevu 33, gdje se vodik malonat spoja I priprema u alkoholnom otapalu, npr. 2-propanolu.
Method according to claim 1, wherein Step B is carried out with EDC x HCl as coupling agent in a THF / NMP solvent mixture. 
Metoda u skladu s patentnim zahtjevom 1, pri čemu se korak 8 izvodi s EDC x HCI kao reagensom povezivanja u smjesi otapala THF/NMP.
Subsequently, the particle size distribution of the sample was analyzed using laser diffraction (Malvern Mastersizer S, UK). 
Nakon toga je analizirana veličinska raspodjela čestica uzorka uporabom laserske difrakcije (Malvern Mastersizer S, UK).
and acetonitrile is about 1:0.14. 
Hi i acetonitrila iznosi otprilike 1:0,14.
If the protection obtained with the combination of the drugs is higher than the fractional inhibition for two compounds acting independently then synergism is considered to occur. 
Ako je zaštita dobivena kombinacijom lijekova veća od frakcijske inhibicije za dva spoja koji djeluju neovisno, smatra se da je došlo do sinergije.
reacting said compound of formula (V) with a compound of the formula (VII): 
(c) stavljanjem u reakciju navedenog spoja formule (V) sa spojem formule (VII):
This invention relates to a recoil damper system. 
Ovaj izum se odnosi na sustav za prigušivanje trzanja oružja.
The arrester according to claim 1, characterized in that the insulating body is shaped as a bar, a strip or a cylinder. 
Gromobran u skladu s patentnim zahtjevom 1, naznačen time što izolirajuće tijelo (1) ima oblik šipke, trake ili valjka.
Isolated polynucleotide comprising a polynucleotide of SEQ ID NO:5 and a polynucleotide of SEQ ID NO:6. 
Izolirani polinukleotid, naznačen time, da obuhvaća polinukleotid od SEQ ID NO:5 i polinukleotid od SEQ ID NO:6.
A substrate according to claim 8 or 9, characterized in that the substrate (S) is a security document such as a bank note, a value document, an identity document, a card, a tax stamp, a label, or a product. 
Podloga sukladno patentnom zahtjevu 8 ili 9, naznačena time, da je podloga (S) sigurnosni dokument poput novčanice, vrijednosnih dokumenata, identifikacijskih dokumenata, kartica, biljega, oznaka ili proizvoda.
cover shoulder Process for production of aggregated conformation prion protein from native conformation prion protein by contacting native conformation prion protein with aggregated conformation prion protein in a liquid composition and subjecting the liquid composition to at least one cycle comprising the generation of shear force and a resting phase, characterized in that the shear force is applied to each volume element of the liquid composition and consists of one uniform shear-force intensity having an intensity range of maximally 10% of one shear-force value. 
Postupak proizvodnje prionskog proteina agregirane konformacije iz prionskog proteina nativne konformacije putem dovođenja proteina priona nativne konformacije u kontakt s prionskim proteinom agregirane konformacije u tekućem sastavu i podvrgavanje tekućeg sastava barem jednom ciklusu koji se sastoji od generiranja sile smicanja i faze odmora, naznačeno time da se sila smicanja primjenjuje na svaki element volumena tekućeg sastava 1 sastoji se od jedne uniformne jačine sile smicanja s intenzitetom raspona od maksimalno 10% vrijednosti sile smicanja.
The bacterial species Roseburia hominis for use according to claim 1 wherein the bacterial species is for use in treating a disorder selected from an inflammatory disorder, an immune disorder and an intestinal disorder in a subject. 
Bakterijska vrsta Roseburia hominis za upotrebu prema zahtjevu 1 naznačena time što je bakterija za upotrebu u liječenju poremećaja odabranog od upalnog poremećaja, imunog poremećaja 1 crijevnog poremećaja kod subjekta.
or, wherein the synthetic GLA adjuvant has the following structure: or a pharmaceutically acceptable salt thereof. 
i R4 su C9-C20 alkil; ili, gdje sintetski GLA ima sljedeću strukturu:
The wear assembly to claim 8, characterized in that the elongate lock (16) is generally parallel to the longitudinal axis (28) in a first plane and inclined to the longitudinal axis (28) in a second transverse plane. 
Potrošni sklop u skladu s patentnim zahtjevom 8, naznačen time što je izduljena brava (16) općenito paralelna u odnosu na uzdužnu os (28) u prvoj razini i nagnuta u odnosu na uzdužnu os (28) u drugoj poprečnoj razini.
A pharmaceutical composition for use in a method of treating metabolic acidosis, wherein the pharmaceutical composition comprises a proton-binding, crosslinked amine polymer comprising the residue of an amine corresponding to Formula 2b and the crosslinked amine polymer is prepared by radical polymerization of an amine corresponding to Formula 2b: wherein 
Farmaceutski pripravak za upotrebu prema bilo kojem od zahtjeva 1-3, naznačen time da umreženi aminski polimer sadrži ostatak amina koji odgovara formuli 1a i umreženi aminski polimer je dobiven radikalnom polimerizacijom amina koji odgovara formuli 1a:
vegetable oils selected from the group consisting of coconut oil, corn oil, cottonseed oil, olive oil, palm oil, peanut oil, rapeseed oil, canola oil, safflower oil, sesame oil, soybean oil, sunflower oil, almond oil, beech nut oil, cashew oil, hazelnut oil, macadamia oil, pine nut oil, pistachio oil, walnut oil, citrus oils, grapefruit seed oil, lemon oil, orange oil, castor oil, hemp oil, mustard oil, radish oil, rice bran oil, salicornia oil, soybean oil, jatropha oil, jojoba oil, linseed oil, poppy oil, stillingia oil, fruit tree oil, artichoke oil, carrot seed oil, mango oil and sea-buckthorn oil; 
- biljna ulja kao što je kokosovo ulje, kukuruzno ulje, ulje sjemenki pamuka, maslinovo ulje, palmino ulje, ulje kikirikija, ulje sjemenki uljane repice, ulje uljane repice, ulje šafranike, ulje sezama, sojino ulje, suncokretovo ulje, bademovo ulje, ulje sjemenki bukve, ulje Anacardium occidentale, ulje lješnjaka, ulje makadamije, ulje pinjola, ulje pistacija, ulje orata, ulja citrusa, ulje sjemenki grejpa, ulje limuna, ulje naranče, ricinusovo ulje, ulje konoplje, ulje gorušice, uije rotkvice, ulje zrna riže, ulje caklenjače, ulje jatrofine, ulje jojobe, ulje sjemenki lana, ulje maka, ulje Sapium sebirefum, ulje voćke, ulje artičake, ulje sjemenki mrkve, ulje manga te ulje morske pasjakovine;
The first circuit section 1a transmits telegrams to beacons, while the second circuit section 1b tests correct operation of data transmission device 1. 
Prva sekcija komunikacijskih krugova la prenosi telegrame prema balizama, dok druga sekcija komunikacijskih krugova 1 b testira točnost rada naprave 1 za prijenos podataka.
A peptide mixture according to any one of claims 1-3, a T-cell mixture according to claim 4 or a pharmaceutical composition according to claim 5, for use in the prophylaxis and/or treatment of cancer, wherein the cancer is colorectal, lung and/or pancreatic cancer. 
Peptidna smjesa u skladu sa bilo kojim od patentnih zahtjeva 1-3, smjesa T stanica u skladu sa patentnim zahtjevom 4 ili farmaceutska kompozicija u skladu sa patentnim zahtjevom 5, za primjenu u profilaksi i/ili
not thermal calendered polyester fibers, with a basis weight ranging from 100 g/m2 to 1000 g/m2, 
netoplinski kalandrirana poliesterska vlakna, osnovne težine od 100 g/m² do 1000 g/m²,
A system for vaporizing a vaporizable substance from a material, the vaporizable substance being subject to vaporization upon receiving electromagnetic energy, the system comprising two or more of the apparatuses of claim 2 arranged in series, wherein the apparatuses of the series are adapted to deliver electromagnetic energy of different field strengths and/or frequencies. 
Sustav za isparavanje isparive dielektrične tvari iz materijala, pri čemu se ispariva dielektrična tvar podvrgava isparavanju prilikom izlaganja mikrovalnoj energiji, a sustav sadrži dva ili više uređaja (10) prema bilo kojem patentnom zahtjevu od 1 do 12 postavljenih u seriji, naznačen time, što su aparati (10) iz serije poželjno prilagođeni za isporuku mikrovalne energije različite jačine polja i/ili frekvencije.
UV monitor (optical path Length 2.5 mm) equipped with a two channel recorder (Amersham Biosciences or equivalent); 
- < UV monitor (duljina optičkog puta 2.5 mm) opremljen s dvo kanalnim snimačem (Amersham Biosciences ili neki ekvivalent);
transmitting the modulated data pseudo-streams through respective transmission channels Ch# 1 . . . 
prijenosa navedenih moduliranih pseudo-tokova podataka preko odgovarajućih prijenosnih kanala (Ch#1...
Such colourants are commonly used in the field of manufacture of polymer, including elastomer, products and the mixture of pigment and carrier material is known in the art as a “masterbatch”. 
Takva sredstva za bojenje se obično koriste u području proizvodnje polimera, uključujući elastomere, a mješavina pigmenta i materijala nosioca je poznata u ovoj struci kao glavna šarža.
28.9 39 Process according to claim 8, wherein compound (I) of polymorphic form K has an average particle size in the range of 2 to 20 µm, preferably 2 to 15 µm, more preferably 5 to 10 µm. 
Postupak prema zahtjevu 8, naznačen time, da spoj (I) u polimorfnom obliku K ima prosječnu veličinu čestice u rasponu od 2 do 20 um, poželjno od 2 do 15 um, prvenstveno od 5 do 10 um.